<DOC>
	<DOCNO>NCT01903265</DOCNO>
	<brief_summary>TNX-102 capsule [ formerly know low dose ( VLD ) cyclobenzaprine ] bedtime show promise treatment fibromyalgia , drug require new formulation technology bedtime use . The present trial design assess safety efficacy TNX-102 SL 2.8 mg tablet , take daily bedtime 12 week treat fibromyalgia .</brief_summary>
	<brief_title>BEdtime Sublingual TNX-102 SL Fibromyalgia Intervention Therapy ( BESTFIT )</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Diagnosis primary Fibromyalgia ( ACR criterion ) Male female 1865 year old For patient major depressive disorder : clinically stable , suicidal risk stable antidepressent therapy Willing able withdraw specific therapy ( ask PI ) Medically acceptable form contraception ( female ) Signed informed consent Arthritis , lupus systemic autoimmune diseases Regional persistent pain could interfere assessment fibromyalgia pain Bipolar psychotic disorder Increased risk suicide Significant clinical ( cardiac , systemic infection , systemic corticosteroid requirement , drug/alcohol abuse ) laboratory abnormality . Inability washoff specific medication ( ask PI ) Known hypersensitivity cyclobenzaprine Others : seizure disorder , sleep apnea , continuous positive airway pressure ( CPAP ) use , BMI &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>sleep</keyword>
</DOC>